Model clinical parameters
| Parameter . | Base-case estimate . | Range . | Study or data source . |
|---|---|---|---|
| PFS for CAR T-cell therapy (axi-cel) | Log-normal: μ = 3.7836, σ = 1.8214 | — | Jacobson et al, 20228 |
| PFS for SOC therapies | Gompertz: λ = 0.0514, γ = −0.0289 | — | Casulo et al, 202210 |
| PFS for PI3K inhibitor (copanlisib) | Weibull: λ = 0.0442, κ = 1.0770 | — | Dreyling et al, 202015 |
| PFS for EZH2 inhibitor (tazemetostat), wild-type | Log-normal: μ = 2.1452, σ = 1.3242 | — | Morschhauser et al, 202014 |
| PFS for EZH2 inhibitor (tazemetostat), mutation | Log-normal: μ = 2.2847, σ = 1.0814 | — | Morschhauser et al, 202014 |
| Time from progression to start of next therapy, mo | 6 | 3-12 | Nastoupil et al, 201428 |
| Median starting age of cohort, y | 60 | 58-62 | Jacobson et al, 20228 |
| Probability of background death, % | — | — | Arias and Xu, 202029 |
| Discount rate, % | 3 | 1.5-6.0 | Sanders et al, 201620; Huntington et al, 201821 |
| Probability of EZH2 mutation, % | 20 | 16-24 | Morschhauser et al, 202014 |
| Recipients of CAR T-cell therapy receiving 12 mo of IVIG, % | 27 | 21.6-32.4 | Jacobson et al, 20228 |
| Probability of dose reduction of PI3K inhibitor, monthly, % | 4.34 | 3.47-5.21 | Dreyling et al, 202015 |
| Probability of dose reduction of EZH2 inhibitor, monthly, % | 0.41 | 0.32-0.49 | Morschhauser et al, 202014 |
| Reduced dose (PI3K inhibitor and EZH2 inhibitor), % | 75 | 60-90 | Expert opinion; FDA package inserts30 |
| Probability of discontinuation of PI3K inhibitor, monthly, % | 4.12 | 3.30-4.94 | Dreyling et al, 202015 |
| Probability of discontinuation of EZH2 inhibitor, monthly, % | 0.23 | 0.18-0.28 | Morschhauser et al, 202014 |
| Probability of CAR T-cell therapy–related mortality (first mo), % | 0.68 | 0.54-0.81 | Jacobson et al, 20228 |
| Probability of receipt of bridging therapy (first mo), % | 4.65 | 3.78-5.58 | Jacobson et al, 20228 |
| Probability of procession to BSC after progression, % | 11.6 | 9.28-13.9 | Barnes et al, 201831 |
| Probability of death from BSC state, monthly, % | 55 | 25-60 | Odejide et al, 201632; expert opinion |
| Parameter . | Base-case estimate . | Range . | Study or data source . |
|---|---|---|---|
| PFS for CAR T-cell therapy (axi-cel) | Log-normal: μ = 3.7836, σ = 1.8214 | — | Jacobson et al, 20228 |
| PFS for SOC therapies | Gompertz: λ = 0.0514, γ = −0.0289 | — | Casulo et al, 202210 |
| PFS for PI3K inhibitor (copanlisib) | Weibull: λ = 0.0442, κ = 1.0770 | — | Dreyling et al, 202015 |
| PFS for EZH2 inhibitor (tazemetostat), wild-type | Log-normal: μ = 2.1452, σ = 1.3242 | — | Morschhauser et al, 202014 |
| PFS for EZH2 inhibitor (tazemetostat), mutation | Log-normal: μ = 2.2847, σ = 1.0814 | — | Morschhauser et al, 202014 |
| Time from progression to start of next therapy, mo | 6 | 3-12 | Nastoupil et al, 201428 |
| Median starting age of cohort, y | 60 | 58-62 | Jacobson et al, 20228 |
| Probability of background death, % | — | — | Arias and Xu, 202029 |
| Discount rate, % | 3 | 1.5-6.0 | Sanders et al, 201620; Huntington et al, 201821 |
| Probability of EZH2 mutation, % | 20 | 16-24 | Morschhauser et al, 202014 |
| Recipients of CAR T-cell therapy receiving 12 mo of IVIG, % | 27 | 21.6-32.4 | Jacobson et al, 20228 |
| Probability of dose reduction of PI3K inhibitor, monthly, % | 4.34 | 3.47-5.21 | Dreyling et al, 202015 |
| Probability of dose reduction of EZH2 inhibitor, monthly, % | 0.41 | 0.32-0.49 | Morschhauser et al, 202014 |
| Reduced dose (PI3K inhibitor and EZH2 inhibitor), % | 75 | 60-90 | Expert opinion; FDA package inserts30 |
| Probability of discontinuation of PI3K inhibitor, monthly, % | 4.12 | 3.30-4.94 | Dreyling et al, 202015 |
| Probability of discontinuation of EZH2 inhibitor, monthly, % | 0.23 | 0.18-0.28 | Morschhauser et al, 202014 |
| Probability of CAR T-cell therapy–related mortality (first mo), % | 0.68 | 0.54-0.81 | Jacobson et al, 20228 |
| Probability of receipt of bridging therapy (first mo), % | 4.65 | 3.78-5.58 | Jacobson et al, 20228 |
| Probability of procession to BSC after progression, % | 11.6 | 9.28-13.9 | Barnes et al, 201831 |
| Probability of death from BSC state, monthly, % | 55 | 25-60 | Odejide et al, 201632; expert opinion |